Angus J.M. Cameron

This study identifies PKN2 as a regulator of tight junctions that limits colitis and colorectal cancer by maintaining intestinal barrier integrity during inflammation.

This study shows that inhibiting Ephrin signaling disrupts stromal-cancer interactions and reduces metastasis in pancreatic cancer using mouse models.

The PRKCA D463H mutation, an inactivating kinase mutation, acts as a gain-of-function oncogenic driver in mice, promoting chondrosarcoma through non-catalytic mechanisms.

This study shows that PKN2 deficiency causes prenatal congenital cardiomyopathy and impairs angiotensin II-induced cardiac hypertrophy in adult mice.